JP7204649B2 - 線維症治療剤 - Google Patents

線維症治療剤 Download PDF

Info

Publication number
JP7204649B2
JP7204649B2 JP2019532895A JP2019532895A JP7204649B2 JP 7204649 B2 JP7204649 B2 JP 7204649B2 JP 2019532895 A JP2019532895 A JP 2019532895A JP 2019532895 A JP2019532895 A JP 2019532895A JP 7204649 B2 JP7204649 B2 JP 7204649B2
Authority
JP
Japan
Prior art keywords
region
bases
strand
nek6
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019532895A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019022257A1 (ja
Inventor
一久 中尾
順一 石山
航 市川
淳 増井
ゆにけ 赤坂
秀一 豊福
亜弥 本田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyorin Pharmaceutical Co Ltd
Original Assignee
Kyorin Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyorin Pharmaceutical Co Ltd filed Critical Kyorin Pharmaceutical Co Ltd
Publication of JPWO2019022257A1 publication Critical patent/JPWO2019022257A1/ja
Application granted granted Critical
Publication of JP7204649B2 publication Critical patent/JP7204649B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2019532895A 2017-07-28 2018-07-30 線維症治療剤 Active JP7204649B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2017146957 2017-07-28
JP2017146957 2017-07-28
PCT/JP2018/028459 WO2019022257A1 (fr) 2017-07-28 2018-07-30 Agent thérapeutique contre la fibrose

Publications (2)

Publication Number Publication Date
JPWO2019022257A1 JPWO2019022257A1 (ja) 2020-05-28
JP7204649B2 true JP7204649B2 (ja) 2023-01-16

Family

ID=65041024

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019532895A Active JP7204649B2 (ja) 2017-07-28 2018-07-30 線維症治療剤

Country Status (16)

Country Link
US (1) US11326163B2 (fr)
EP (1) EP3659609B1 (fr)
JP (1) JP7204649B2 (fr)
KR (1) KR102710473B1 (fr)
CN (1) CN110996969B (fr)
AU (1) AU2018307897B2 (fr)
BR (1) BR112020001412A2 (fr)
CA (1) CA3069406A1 (fr)
CL (1) CL2020000219A1 (fr)
CO (1) CO2020001106A2 (fr)
EA (1) EA202090393A1 (fr)
IL (1) IL272271A (fr)
PH (1) PH12020500198A1 (fr)
SG (1) SG11201913541QA (fr)
TW (1) TW201910514A (fr)
WO (1) WO2019022257A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020152869A1 (fr) * 2019-01-25 2020-07-30 杏林製薬株式会社 Agent thérapeutique contre la fibrose
EP4206325A4 (fr) 2020-08-25 2025-06-04 Tsumugi kosan K.K. Nouvelle molécule d'acide nucléique inhibant l'expression d'un gène cible
CN118562801B (zh) * 2024-06-13 2025-03-14 南通大学附属医院 治疗卵巢癌的siRNA分子

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040097441A1 (en) 2002-11-16 2004-05-20 Isis Pharmaceuticals Inc. Modulation of NIMA-related kinase 6 expression
WO2012017919A1 (fr) 2010-08-03 2012-02-09 株式会社ボナック Molécule d'acide nucléique simple brin ayant un squelette alicyclique contenant de l'azote

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US7485468B2 (en) 2004-10-15 2009-02-03 Galapagos Bv Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
EP2933333B1 (fr) 2010-07-08 2018-02-21 Bonac Corporation Molécule d'acide nucléique monocaténaire destinée à réguler l'expression génique
US9315799B2 (en) 2011-05-10 2016-04-19 Bonac Corporation Process for preparing phosphate compound bearing isotope
MX370398B (es) 2011-08-25 2019-12-11 Bonac Corp Compuesto de glicosido, metodo para producir tioeter, eter, metodo para producir eter, metodo para producir un compuesto de glicosido, metodo para producir acido nucleico.
CN104039961A (zh) 2012-01-07 2014-09-10 株式会社博纳克 具有氨基酸骨架的单链核酸分子
WO2013180038A1 (fr) 2012-05-26 2013-12-05 株式会社ボナック Molécule d'acide nucléique simple brin pour réguler l'expression d'un gène ayant une fonction d'administration
EP2972381A2 (fr) 2013-03-14 2016-01-20 Galapagos NV Cibles et composés moléculaires, et procédés pour les identifier, utiles dans le traitement de maladies associées à une transition épithélio-mésenchymateuse
JP2017510552A (ja) 2014-02-07 2017-04-13 イーフェクター セラピューティクス， インコーポレイテッド 線維性疾患を治療するための方法
BR112017014090A2 (pt) 2014-12-29 2018-03-06 Bonac Corporation composição, e, métodos para produção de uma composição e estabilização de uma molécula de ácido nucleico.
WO2016158809A1 (fr) 2015-03-27 2016-10-06 株式会社ボナック Molécule d'acide nucléique monocaténaire ayant une fonction d'administration et une capacité à réguler l'expression génique
US10377788B2 (en) 2015-04-02 2019-08-13 Bonac Corporation Method for producing glycoside compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040097441A1 (en) 2002-11-16 2004-05-20 Isis Pharmaceuticals Inc. Modulation of NIMA-related kinase 6 expression
WO2012017919A1 (fr) 2010-08-03 2012-02-09 株式会社ボナック Molécule d'acide nucléique simple brin ayant un squelette alicyclique contenant de l'azote

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BMB reports，2015年，Vol.48, No.8, pp.473-478
PloS one，2014年，Vol.9, No.4, e96095

Also Published As

Publication number Publication date
US11326163B2 (en) 2022-05-10
AU2018307897A1 (en) 2020-01-30
CL2020000219A1 (es) 2020-07-24
EP3659609A4 (fr) 2021-04-21
CN110996969B (zh) 2023-02-28
EP3659609A1 (fr) 2020-06-03
PH12020500198A1 (en) 2020-09-28
EA202090393A1 (ru) 2020-05-20
IL272271A (en) 2020-03-31
CA3069406A1 (fr) 2019-01-31
SG11201913541QA (en) 2020-02-27
EP3659609B1 (fr) 2024-05-08
CO2020001106A2 (es) 2020-02-18
US20210087556A1 (en) 2021-03-25
KR20200033927A (ko) 2020-03-30
WO2019022257A1 (fr) 2019-01-31
KR102710473B1 (ko) 2024-10-02
CN110996969A (zh) 2020-04-10
JPWO2019022257A1 (ja) 2020-05-28
TW201910514A (zh) 2019-03-16
AU2018307897B2 (en) 2024-01-25
BR112020001412A2 (pt) 2020-08-04

Similar Documents

Publication Publication Date Title
KR101894702B1 (ko) 함질소 지환식 골격을 갖는 일본쇄 핵산 분자
RU2697094C2 (ru) ИСКУССТВЕННАЯ мкРНК С СООТВЕТСТВИЕМ ДЛЯ КОНТРОЛЯ ЭКСПРЕССИИ ГЕНОВ И ЕЕ ПРИМЕНЕНИЕ
KR20130090792A (ko) 유전자 발현 제어를 위한 일본쇄 핵산 분자
JP6808710B2 (ja) 核酸分子を安定に含有する組成物
JP6471176B2 (ja) 遺伝子発現制御のための天然型ｍｉＲＮＡおよびその用途
US20200038427A1 (en) Cyclic nucleic acid molecule having gene expression control function
JP7204649B2 (ja) 線維症治療剤
JP2013055913A (ja) 遺伝子発現制御のための一本鎖ｒｎａ分子
JP7241098B2 (ja) 線維症治療剤
WO2013133393A1 (fr) Molécule d'acide nucléique à simple brin pour l'inhibition de l'expression du gène vegf

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20191011

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210608

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220712

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220830

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221213

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221228

R150 Certificate of patent or registration of utility model

Ref document number: 7204649

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

S801 Written request for registration of abandonment of right

Free format text: JAPANESE INTERMEDIATE CODE: R311801

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

ABAN Cancellation due to abandonment
R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350